Brown cites those two companies in particular due to their looming battle for market share in the lucrative GLP-1 receptor agonist space set to explode in weight loss (Evaluate projects the global obesity market to reach close to $50 billion by 2028, with a compound annual growth rate of 36% until then). And you’ll see others-like Novo and Lilly-come in, I think,” Amy Brown, special reports and projects editor, Evaluate Vantage, tells Pharm Exec. “It will be the ones around the bottom that might drop out of the top 10. It also includes each company’s top-selling drugs and R&D investment totals. The data for this year’s list was again provided in partnership with Evaluate Ltd. But one thing appears certain: By the end of the decade, the complexion of our Pharm Exec 50 will likely appear vastly different. It’s the second story, of course, that is still being written-and predicting pharma narratives is never easy. The other, when peeking beneath the data, foretells a recalibration of sorts that seems to be materializing, with non-pandemic treatment trends, market drivers, and macroeconomic and geopolitical factors once again taking center stage in driving future fortunes-and potential risers and other compelling shuffling to our list in the years ahead.

One is readily apparent, as the numbers reflect-capturing most recent full-year drug revenue performance (in this case, 2022)-and the tipping point or subsequent decent down the COVID-19 product cliff.

This year’s rankings of the top 50 global biopharma players based on prescription drug sales, our 23rd such installment, paints two distinctly different pictures concerning the trajectory of the industry’s commercial output and product direction.

Adobe air end of life